<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01057017</url>
  </required_header>
  <id_info>
    <org_study_id>BrUOG-CR-218</org_study_id>
    <nct_id>NCT01057017</nct_id>
  </id_info>
  <brief_title>Panitumumab and Bevacizumab Maintenance After First-Line FOLFOX-Bevacizumab for Patients With Advanced Colorectal Cancer With Wild-Type Ras</brief_title>
  <official_title>Panitumumab and Bevacizumab Maintenance After First-Line FOLFOX-Bevacizumab for Patients With Advanced Colorectal Cancer With Wild-Type Ras</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Brown University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Rhode Island Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Miriam Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Brown University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Bevacizumab given at 7.5mg/kg. IV over 10-90 minutes every 3 weeks until disease
      progression.Panitumumab given at 9mg/kg. IV over 30-90 minutes every 3 weeks until disease
      progression.Primary Objective: To determine the safety of every 3 week panitumumab and
      bevacizumab as maintenance therapy for patients with metastatic colorectal cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      26 patients with advanced colorectal cancer will be given Bevacizumab at 7.5mg/kg. IV over
      10-90 minutes every 3 weeks until disease progression.Panitumumab given at 9mg/kg. IV over
      30-90 minutes every 3 weeks until disease progression
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    possible lack of efficacy
  </why_stopped>
  <start_date>January 2010</start_date>
  <completion_date type="Actual">December 2011</completion_date>
  <primary_completion_date type="Actual">April 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Patients With Toxicity to Combination of Panitumumab and Bevacizumab</measure>
    <time_frame>every 3 weeks until patient comes off study (progressive disease), for up to 2 years</time_frame>
    <description>To determine the safety of every 3 week panitumumab and bevacizumab as maintenance therapy for patients with metastatic colorectal cancer. Use of CTCAE version 3</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">5</enrollment>
  <condition>Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Bevacizumab: 7.5mg/kg, IV over 30-90 minutes every 3 weeks until disease progression.
Panitumumab Dose Level 1: 6mg/kg over 60-120 minutes every 3 weeks until disease progression Dose Level 2: 9mg/kg over 60-120 minutes every 3 weeks until disease progression</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>intervention</intervention_name>
    <arm_group_label>intervention</arm_group_label>
    <other_name>Bevacizumab: 7.5mg/kg, IV over 30-90 minutes every 3 weeks until disease progression.</other_name>
    <other_name>Panitumumab</other_name>
    <other_name>Dose Level 1: 6mg/kg over 60-120 minutes every 3 weeks until disease progression</other_name>
    <other_name>Dose Level 2: 9mg/kg over 60-120 minutes every 3 weeks until disease progression</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Histologically or pathologically confirmed advanced colorectal cancer who received
             FOLFOX/bevacizumab for first-line treatment of metastatic disease.

          2. Patients must not have had disease progression while receiving a minimum of 6
             treatments of FOLFOX/bevacizumab. Patients with stable or responding disease on
             FOLFOX/bevacizumab are eligible. Bevacizumab does not need to be administered with all
             cycles of FOLFOX.

          3. At least 3 weeks since prior FOLFOX/bevacizumab.

          4. Wild type ras

          5. No potentially curative treatment option.

          6. ECOG performance status 0-1

          7. Age&gt;18, not pregnant or breast-feeding

          8. Required entry laboratory parameters within 14 days of study entry: Granulocytes ≥
             1500/µl; platelet count ≥ 100,000/µl, Creatinine ≤ 2.0 mg/dl, Bilirubin ≤ 1.5 x upper
             limit of normal, AST ≤ 3 x upper limit of normal (or ≤ 5 x upper limit of normal for
             patients with liver metastases), Magnesium &gt; lower limit of normal

          9. Life expectancy of at least 16 weeks

         10. Must not have uncontrolled severe, intercurrent illness.

         11. No chemotherapy or radiation therapy within last 3 weeks

         12. No concurrent anticancer therapy.

         13. Signed study-specific consent form prior to study entry

        Exclusion Criteria:

          1. Prior EGFR inhibitor and prior irinotecan.

          2. Clinically significant cardiac disease (e.g., uncontrolled hypertension [blood
             pressure of &gt;150/90 mmHg on medication], history of myocardial infarction within 6
             months,), New York Heart Association (NYHA) Class II or greater congestive heart
             failure within 6 months, unstable arrhythmia. Patients with an atrial arrhythmia must
             have this condition well controlled on stable medication. Patients with current or
             recent (within 6 months) unstable angina are also not eligible.

          3. Significant bleeding diathesis or coagulopathy

          4. Major surgical procedure within 28 days prior to start of treatment. Port-a-cath
             placements are allowed.

          5. Serious, nonhealing wound, ulcer, or current healing fracture

          6. History of cerebral aneurysms or cerebral arteriovenous malformations.

          7. Patients with recent (within 12 months) arterial thromboembolic events, including
             transient ischemic attack (TIA), cerebrovascular accident (CVA), or clinically
             significant peripheral artery disease should also be excluded.

          8. Brain metastases

          9. Patients with a history of a gastrointestinal fistula or perforation.

         10. Significant infection or other coexistent medical condition that would preclude
             protocol therapy.

         11. Interstitial lung disease

         12. Patients who have had an organ transplant

         13. Known positive test(s) for HIV infection, hepatitis C virus, acute or chronic active
             hepatitis B infection

         14. Women of childbearing potential and men who are sexually active and not willing/able
             to use medically acceptable forms of contraception; this exclusion is necessary
             because the treatment involved in this study may be significantly teratogenic.

         15. Prior invasive malignancy (except non-melanomatous skin cancer) unless disease free
             for a minimum of 2 years (For example, carcinoma in situ of the breast, bladder and
             cervix are permissible).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>howard p safran, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>lifespan Hospitals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Rhode Island Hospital</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02906</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 20, 2010</study_first_submitted>
  <study_first_submitted_qc>January 26, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2010</study_first_posted>
  <results_first_submitted>May 9, 2013</results_first_submitted>
  <results_first_submitted_qc>October 9, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 4, 2013</results_first_posted>
  <last_update_submitted>June 18, 2014</last_update_submitted>
  <last_update_submitted_qc>June 18, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 27, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Brown University</investigator_affiliation>
    <investigator_full_name>howard safran</investigator_full_name>
    <investigator_title>Director of BrUOG</investigator_title>
  </responsible_party>
  <keyword>colorectal cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>5 Patients were enrolled at The Miriam and Rhode Island Hospital</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Panitumumab and Bevacizumab</title>
          <description>Bevacizumab: 7.5mg/kg, IV over 30-90 minutes every 3 weeks until disease progression.
Panitumumab Dose Level 1: 6mg/kg over 60-120 minutes every 3 weeks until disease progression Dose Level 2: 9mg/kg over 60-120 minutes every 3 weeks until disease progression</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Intervention</title>
          <description>Bevacizumab: 7.5mg/kg, IV over 30-90 minutes every 3 weeks until disease progression.
Panitumumab Dose Level 1: 6mg/kg over 60-120 minutes every 3 weeks until disease progression Dose Level 2: 9mg/kg over 60-120 minutes every 3 weeks until disease progression</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="5"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="54" spread="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Patients With Toxicity to Combination of Panitumumab and Bevacizumab</title>
        <description>To determine the safety of every 3 week panitumumab and bevacizumab as maintenance therapy for patients with metastatic colorectal cancer. Use of CTCAE version 3</description>
        <time_frame>every 3 weeks until patient comes off study (progressive disease), for up to 2 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Panitumumab and Bevacizumab</title>
            <description>Bevacizumab: 7.5mg/kg, IV over 30-90 minutes every 3 weeks until disease progression.
Panitumumab Dose Level 1: 6mg/kg over 60-120 minutes every 3 weeks until disease progression Dose Level 2: 9mg/kg over 60-120 minutes every 3 weeks until disease progression</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Toxicity to Combination of Panitumumab and Bevacizumab</title>
          <description>To determine the safety of every 3 week panitumumab and bevacizumab as maintenance therapy for patients with metastatic colorectal cancer. Use of CTCAE version 3</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>from time of signing consent to 30 days post last dose of drug (occurred up to approximately 10 months)</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Intervention</title>
          <description>Bevacizumab: 7.5mg/kg, IV over 30-90 minutes every 3 weeks until disease progression.
Panitumumab Dose Level 1: 6mg/kg over 60-120 minutes every 3 weeks until disease progression Dose Level 2: 9mg/kg over 60-120 minutes every 3 weeks until disease progression</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Anorexia (3), nausea(3), vomiting(2), weakness(3), confusion(1), hypok(3), hypophos(3), hypoca(3)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Skin Redness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Yeast Infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Alk Phos</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>AST</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>dehydration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>abd pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Howard Safran, MD</name_or_title>
      <organization>BrUOG</organization>
      <phone>4018633000</phone>
      <email>Hsafran@lifespan.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

